Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 20:7:97.
doi: 10.1186/1748-717X-7-97.

Is the in vivo dosimetry with the OneDosePlusTM system able to detect intra-fraction motion? A retrospective analysis of in vivo data from breast and prostate patients

Maria Daniela Falco  1 , Marco D'Andrea, Alessia Lo Bosco, Mauro Rebuzzi, Elisabetta Ponti, Barbara Tolu, Grazia Tortorelli, Rosaria Barbarino, Luana Di Murro, Riccardo Santoni
Affiliations

Is the in vivo dosimetry with the OneDosePlusTM system able to detect intra-fraction motion? A retrospective analysis of in vivo data from breast and prostate patients

Maria Daniela Falco et al. Radiat Oncol. .

Abstract

Background: The OneDosePlusTM system, based on MOSFET solid-state radiation detectors and a handheld dosimetry reader, has been used to evaluate intra-fraction movements of patients with breast and prostate cancer.

Methods: An Action Threshold (AT), defined as the maximum acceptable discrepancy between measured dose and dose calculated with the Treatment Planning System (TPS) (for each field) has been determined from phantom data. To investigate the sensitivity of the system to direction of the patient movements, fixed displacements have been simulated in phantom. The AT has been used as an indicator to establish if patients move during a treatment session, after having verified the set-up with 2D and/or 3D images. Phantom tests have been performed matching different linear accelerators and two TPSs (TPS1 and TPS2).

Results: The ATs have been found to be very similar (5.0% for TPS1 and 4.5% for TPS2). From statistical data analysis, the system has been found not sensitive enough to reveal displacements smaller than 1 cm (within two standard deviations). The ATs applied to in vivo treatments showed that among the twenty five patients treated for breast cancer, only four of them moved during each measurement session. Splitting data into medial and lateral field, two patients have been found to move during all these sessions; the others, instead, moved only in the second part of the treatment. Patients with prostate cancer have behaved better than patients with breast cancer. Only two out of twenty five moved in each measurement session.

Conclusions: The method described in the paper, easily implemented in the clinical practice, combines all the advantages of in vivo procedures using the OneDosePlusTM system with the possibility of detecting intra-fraction patient movements.

PubMed Disclaimer

Figures

Figure 1
Figure 1
OneDosePlusTM system. The system comprises single p-type wireless MOSFET detectors and a handheld reader.
Figure 2
Figure 2
Breast treatment. MOSFET detector positioned at the surface projection of the isocenter on a patient treated for breast cancer (lateral field).
Figure 3
Figure 3
Prostate treatment. MOSFET detector positioned at the surface projection of the isocenter on a patient treated for prostate cancer (90° field).
Figure 4
Figure 4
Breast treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system, for both medial and lateral fields along the entire treatment course.
Figure 5
Figure 5
Breast treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system, for the medial field along the entire treatment course.
Figure 6
Figure 6
Breast treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system, for the lateral field along the entire treatment course.
Figure 7
Figure 7
Prostate treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system along the entire treatment course.
Figure 8
Figure 8
Prostate treatment with the Elekta Synergy S. Average discrepancy using TPS2 and a 3D-CBCT verification system along the entire treatment course.
See this image and copyright information in PMC

References

    1. Protection of the patient in radiation therapy. ICRP publication 44. International Commission on Radiological Protection (ICRP) Ann ICRP. 1985;15:2. - PubMed
    1. Belleti S, Dutreix A, Garavaglia G, Gfirtner H, Haywood HJ, Jessen KA, Lamm I-L, Mijnheer B, Noël A, Nüsslin F, Rosenow U, Schneider P, Seelentag W, Sheriff S, Svensson H, Thwaites H. Quality assurance in radiotherapy: the importance of medical physics staffing levels. Recommendations from an ESTRO/EFOM joint task group. Radiother Oncol. 1996;41:89–94. - PubMed
    1. Yorke E, Alecu R, Fontenla D, Ding L, Kalend A, Kaurin D, Diode in vivo dosimetry for patients receiving external beam radiotherapy: recommendations of the AAPM radiation therapy committee. Task group 62. Medical Physics Publishing; 2005.
    1. Garavaglia G, Johansonn KA, Leunens G, Mijnheer BJ. The role of in-vivo dosimetry. Radiother Oncol. 1993;29:281–282. doi: 10.1016/0167-8140(93)90259-B. - DOI - PubMed
    1. Huyskens DP, Bogaerts R, Verstraete J, Leaf M, Nystrom H, Fiorino C, Broggi S, Jornet N, Ribas M, Thwaites DI. Practical guidelines for the implementation of in vivo dosimetry with diode in external radiotherapy with photon beams (entrance dose) 2001.